Accelerating
Precision Oncology
From translational research to clinical development to commercialization, we meet your needs at every stage of drug development.
Accelerate Your Commercial Success With a Globally Utilized Portfolio
When commercializing new therapeutics, we understand that access to next-generation sequencing testing can vary significantly by country and region. That’s why we partner with labs and world-renowned cancer centers around the globe to ensure that we can bring our technology platform to new markets while maintaining our high quality and performance standards.
Global Access to Our Proprietary Testing Solutions Is a Top Priority
Countries with a Guardant Health presence
Approvals, demonstrating regulatory expertise
Ordering oncologists
Maintaining High Quality Standards Around the Globe
Accelerating CGP Testing Adoption and Reimbursement in Europe
Guardant360® CDx has received CE certification under the European Union In Vitro Diagnostics Regulation (IVDR). This certification includes CDx indications for identifying patients for targeted therapy in non-small cell lung cancer (NSCLC) breast cancer, and for tumor profiling across all solid tumors.2
Guardant Health has partnered with our public private partnerships in the UK, Spain and Italy to develop a local CGP test leveraging Guardant Health’s technology to expand molecular testing access in Europe.
Panel Talk: Unlocking Global Access to Liquid Biopsy Through In-Country Testing
Explore how we're helping biopharma companies execute diverse clinical trials with a globally validated liquid biopsy.
Learn MoreMeet Our Global Partners in CGP Testing
Hear how our partners in the UK and China are expanding access to in-country liquid comprehensive genomic profiling (CGP) testing by leveraging Guardant Health technology.